

Supplementary Table S1. The concentrations of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and 3-methoxytyramine (3-MT) in the striatum of mice 24 hours after a single injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) at a dose of 40 mg/kg or after each of the successive injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) at increasing doses from 8 to 40 mg/kg. Control group received 0.9% NaCl according to the same schemes.

Group, 0,9% NaCl or MPTP (mg/kg)	Dopamine, pmol/mg	<i>p</i> *	DOPAC, pmol/mg	<i>p</i> *	HVA, pmol/mg	<i>p</i> *	3-MT, pmol/mg	<i>p</i> *
Single injection of MPTP								
Control	103.1 ± 2.0		6.3 ± 0.4		12.0 ± 0.6		2.0 ± 0.2	
40mg/kg	25.4 ± 3.3	1.5E-09	2.7 ± 0.2	7.13E-05	8.1 ± 0.7	1.93E-03	1.1 ± 0.1	2.77E-03
Successive injections of MPTP								
Control	110.4 ± 3.6		9.4 ± 0.2		9.2 ± 0.2		3.1 ± 0.3	
8	91.9 ± 1.9	1.1E-03	8.1 ± 0.4	0.02	8.7 ± 0.5	0.39	2.9 ± 0.1	0.58
8-10	51.8 ± 3.0	1.8E-07	5.3 ± 0.2	3.5E-07	7.4 ± 0.6	0.03	2.3 ± 0.2	0.08
Control	102.1 ± 2.3		6.4 ± 0.4		10.1 ± 1.0		2.7 ± 0.3	
8-10-12	34.1 ± 1.5	3.0E-07	3.0 ± 0.1	1.9E-04	5.5 ± 0.3	1.6E-03	1.8 ± 0.2	0.04
Control	103.2 ± 2.8		8.8 ± 0.2		10.4 ± 0.2		2.7 ± 0.4	
8-10-12-16	31.0 ± 1.6	7.2E-10	3.6 ± 0.2	2.1E-08	6.2 ± 0.5	2.6E-05	1.8 ± 0.3	0.13
Control	98.8 ± 1.9		7.3 ± 0.3		9.8 ± 0.2		3.1 ± 0.1	
8-10-12-16-20	35.1 ± 3.0	5.7E-09	3.9 ± 0.3	1.5E-05	8.2 ± 0.5	0.01	3.4 ± 0.2	0.17
Control	107.5 ± 3.6		6.0 ± 0.4		7.6 ± 0.5		3.1 ± 0.4	
8-10-12-16-20-26	29.1 ± 1.0	4.1E-12	2.5 ± 0.3	0.01	5.3 ± 0.5	0.01	2.0 ± 0.2	6.9E-01
Control	104.6 ± 3.3		7.9 ± 0.2		9.2 ± 0.1		1.6 ± 0.2	
8-10-12-16-20-26-40	26.7 ± 1.2	6.0E-12	2.7 ± 0.3	5.1E-09	6.4 ± 0.7	0.01	0.8 ± 0.1	2.04E-04

*p** calculated relative to the control group.

Supplementary Table S2. The content of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the substantia nigra of mice 24 hours after a single injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) at a dose of 40 mg/kg or after each of the successive injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) at increasing doses from 8 to 40 mg/kg. Control group received 0.9% NaCl according to the same schemes.

Group. 0.9% NaCl or MPTP (mg/kg)	Dopamine. pmol	<i>p</i> *	DOPAC. pmol	<i>p</i> *	HVA. pmol	<i>p</i> *
Single injection of MPTP						
Control	8.9 ± 0.5		2.8 ± 0.2		4.1 ± 0.2	
40	7.0 ± 0.6	0.03	1.9 ± 0.2	0.02	3.9 ± 0.2	0.43
Successive injections of MPTP						
Control	6.9 ± 0.7		2.6 ± 0.2		3.7 ± 0.2	
8	7.5 ± 0.5	0.5	2.1 ± 0.1	0.03	4.5 ± 0.3	0.051
8-10	6.8 ± 0.3	0.94	2.3 ± 0.1	0.23	4.7 ± 0.5	0.11
Control	6.2 ± 0.3		2.3 ± 0.1		3.3 ± 0.3	
8-10-12	5.5 ± 0.4	0.18	1.7 ± 0.0	0.005	2.8 ± 0.2	0.13
Control	7.3 ± 0.4		2.1 ± 0.2		3.2 ± 0.2	
8-10-12-16	5.8 ± 0.4	0.03	1.7 ± 0.2	0.08	2.8 ± 0.2	0.22
Control	8.2 ± 0.4		2.1 ± 0.1		3.3 ± 0.2	
8-10-12-16-20	4.4 ± 0.2	4.9E-05	1.5 ± 0.1	3.7E-04	3.0 ± 0.1	0.30
Control	7.1 ± 0.3		2.4 ± 0.2		2.4 ± 0.1	
8-10-12-16-20-26	7.1 ± 0.3	8.4E-04	1.2 ± 0.2	1.1E-04	2.0 ± 0.2	0.07
Control	7.8 ± 0.5		2.4 ± 0.2		3.4 ± 0.2	
8-10-12-16-20-26-40	4.3 ± 0.3	2.1E-05	1.0 ± 0.1	1.0E-08	3.5 ± 0.2	0.76

*p** calculated relative to the control group.




Figure S1. The number of tyrosine hydroxylase (TH)-immunopositive neurons in the substantia nigra 24 hours and 5 days after successive MPTP injections at increasing doses from 8 to 40 mg/kg ("n" per group = 5). * $p < 0.05$, significant differences compared with the control (Mann-Whitney U-test).